Log Out

Geron cancer drug meets midstage study goals

Tue Dec 8, 2009 6:06 PM EST
, , ,
Associated Press
Advertise | AdChoices

MENLO PARK — Biotechnology company Geron Corp. said Tuesday its developing cancer treatment GRNVAC1 met safety and tolerability goals in a midstage study.

The drug candidate is actually a developing vaccine, aimed at prompting the immune system to fight tumor cells. The study involves patients with acute myelogenous leukemia, a type of blood and bone marrow cancer.

Shares of Geron rose 12 cents, or 2 percent, to $6.02 in after-hours trading after rising 12 cents to close at $5.90 during the regular trading session.

© 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
  • Enjoy this article? Help vote it up the 'Vine.

Back To Top | Front Page

Published to:

Leave a Comment:
You're in Easy Mode. If you prefer, you can use XHTML Mode instead.
Newsvine Privacy Statement
As a new user, you may notice a few temporary content restrictions. Click here for more info.